Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Khine Z Win, MD, Nathan Wilson, PharmD, David D Stenehjem, PharmD, Natalee Tanner, PharmD, George M. Rodgers, MD PhD, Jeffrey Gilreath, PharmD

Blood (2015) 126 (23): 2319.

https://doi.org/10.1182/blood.V126.23.2319.2319

Published: 2015

Journal Articles

Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease

Simon Mantha, MD, MPH, Jack Ansell, MD

Blood (2013) 122 (21): 3640.

https://doi.org/10.1182/blood.V122.21.3640.3640

Published: 2013

Journal Articles

Comparative Efficacy and Safety Of Dabigatran Etexilate and Rivaroxaban For The Treatment Of Deep Vein Thrombosis and Pulmonary Embolism

Andreas Clemens, MD, Shaun Abeysinghe, PhD, Ann-Katrin Gonschior, PhD, Volker Hösel, PhD, Sarah Lock, BSc, Sorrel E Wolowacz, PhD, Mathew Woods, MSc, Evelina Zimovetz, MSc

Blood (2013) 122 (21): 4807.

https://doi.org/10.1182/blood.V122.21.4807.4807

Published: 2013

Journal Articles

Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE

Martin Gebel, PhD, Martin Prins, MD, Anthonie WA Lensing, MD

Blood (2013) 122 (21): 1135.

https://doi.org/10.1182/blood.V122.21.1135.1135

Published: 2013

Journal Articles

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Bonno van Bellen, MD, Martin Prins, MD, PhD, Luke Bamber, Maria Wang, Anthonie WA Lensing

Blood (2012) 120 (21): 3419.

https://doi.org/10.1182/blood.V120.21.3419.3419

Published: 2012

Journal Articles

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Harry Roger Buller, MD, PhD

Blood (2012) 120 (21): 20.

https://doi.org/10.1182/blood.V120.21.20.20

Published: 2012

Journal Articles

The EINSTEIN DVT Study: Does Localization of the Initial DVT Affect the Occurrence of Recurrent VTE While Patients Are on Anticoagulation?

Martin H Prins, Paolo Prandoni, Anthonie WA Lensing, Bonno van Bellen, Akos F Pap, Gary E Raskob, Harry R Büller

Blood (2011) 118 (21): 207.

https://doi.org/10.1182/blood.V118.21.207.207

Published: 2011

Journal Articles

Oral Rivaroxaban for the Acute and Continued Treatment of Symptomatic Venous Thromboembolism. the Einstein-DVT and Einstein-Extension Study

Harry Roger Buller, MD, PhD

Blood (2010) 116 (21): 187.

https://doi.org/10.1182/blood.V116.21.187.187

Published: 2010

Journal Articles

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Harry R. Buller, Anthonie W. A. Lensing, Martin H. Prins, Giancarlo Agnelli, Alexander Cohen, Alexander S. Gallus, Frank Misselwitz, Gary Raskob, Sebastian Schellong, Annelise Segers

Blood (2008) 112 (6): 2242–2247.

https://doi.org/10.1182/blood-2008-05-160143

Published: 2008

Includes: Supplemental data

Journal Articles

Once- or Twice-Daily Rivaroxaban for the Treatment of Proximal Deep Vein Thrombosis: Similar Efficacy and Safety to Standard Therapy in Dose-Ranging Studies.

Harry R. Büller, MD, Giancarlo Agnelli, MD, the EINSTEIN-DVT ODIXa-DVT Study Groups

Blood (2006) 108 (11): 572.

https://doi.org/10.1182/blood.V108.11.572.572

Published: 2006

NARROW

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease

Comparative Efficacy and Safety Of Dabigatran Etexilate and Rivaroxaban For The Treatment Of Deep Vein Thrombosis and Pulmonary Embolism

Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

The EINSTEIN DVT Study: Does Localization of the Initial DVT Affect the Occurrence of Recurrent VTE While Patients Are on Anticoagulation?

Oral Rivaroxaban for the Acute and Continued Treatment of Symptomatic Venous Thromboembolism. the Einstein-DVT and Einstein-Extension Study

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Once- or Twice-Daily Rivaroxaban for the Treatment of Proximal Deep Vein Thrombosis: Similar Efficacy and Safety to Standard Therapy in Dose-Ranging Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only